Immuron Financials - Benzinga

Immuron Ltd

IMRNNASDAQ

Trade with Public

Trade with Public

$1.10

N/A

At close: Aug 11, 5:00 PM EST

$1.14

0.043.64%

After Hours: Aug 10, 5:08 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Immuron Financials

Immuron (IMRN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Immuron Sees Prelim FY2026 Sales $5.462M

Immuron (NASDAQ:IMRN) sees Prelim FY2026 sales of $5.462 million.

Benzinga Newsdesk

PRO
Immuron H1 EPS $(0.01), Same YoY, Sales $4.184M Up From $3.994M YoY

Immuron (NASDAQ:IMRN) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.184 million in sales this quarter. This is a 4.76 percent increase over

Benzinga Newsdesk

PRO
Immuron Reported Q1 Sales Growth Of 34% On Prior Comparative Period

Sales Highlights (unaudited):Global• Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)Australia • Q1 sales AUD$1.6 million up 52% on pcpCanada• Q1 sales AUD$0.0 million down 92% on

Benzinga Newsdesk

PRO
Immuron Says 2025 Sales Growth Of 49% For Travelan Exceeded Projection

GlobalAnnual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior yearAustralia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on

Benzinga Newsdesk

PRO
Immuron Announces Sales (Unaudited) Of Travelan A$1.5M, Up 13% Prior Quarter, An OTC Immune Supplement Targeting Pathogenic Bacteria And Toxins Produced In The Gastrointestinal Tract

Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia • September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica • September 2024 Quarter

Benzinga Newsdesk

Immuron Announced Travelan Sales Continued Strong Growth

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that

Charles Gross